AstraZeneca Covid-19 Antibody Authorized by FDA as Novel Tool to Prevent Symptomatic Disease

The Wall Street Journal2021-12-09

The U.S. Food and Drug Administration authorized a preventive antibody combination from AstraZeneca AZN 0.68% PLC that has shown strong efficacy in reducing risk of symptomatic Covid-19, offering a ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

BotakTur
2021-12-09
BotakTur
Ok
- BowenDu:
  nice
- BotakTur:
  Ok
Botak Tur
2021-12-09
Botak Tur
K
- Botak Tur:
  K
Kaden0204
2021-12-09
Kaden0204
Ok
SamuelNg
2021-12-09
SamuelNg
like

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1141494008?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-12-09 08:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141494008","market":"us","top_or_hot":-1,"title":"AstraZeneca Covid-19 Antibody Authorized by FDA as Novel Tool to Prevent Symptomatic Disease","media":"The Wall Street Journal","content":"<div>\n<p>The U.S. Food and Drug Administration authorized a preventive antibody combination from AstraZeneca AZN 0.68% PLC that has shown strong efficacy in reducing risk of symptomatic Covid-19, offering a ...</p>\n\n<a href=\"https://www.wsj.com/articles/astrazeneca-covid-19-antibody-authorized-by-fda-as-novel-tool-to-prevent-symptomatic-disease-11639005991?mod=hp_lista_pos4\">网页链接</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca Covid-19 Antibody Authorized by FDA as Novel Tool to Prevent Symptomatic Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca Covid-19 Antibody Authorized by FDA as Novel Tool to Prevent Symptomatic Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-09 08:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.wsj.com/articles/astrazeneca-covid-19-antibody-authorized-by-fda-as-novel-tool-to-prevent-symptomatic-disease-11639005991?mod=hp_lista_pos4><strong>The Wall Street Journal</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The U.S. Food and Drug Administration authorized a preventive antibody combination from AstraZeneca AZN 0.68% PLC that has shown strong efficacy in reducing risk of symptomatic Covid-19, offering a ...</p>\n\n<a href=\"https://www.wsj.com/articles/astrazeneca-covid-19-antibody-authorized-by-fda-as-novel-tool-to-prevent-symptomatic-disease-11639005991?mod=hp_lista_pos4\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AZN","symbol_name":"阿斯利康","start_time":0,"source_url":"https://www.wsj.com/articles/astrazeneca-covid-19-antibody-authorized-by-fda-as-novel-tool-to-prevent-symptomatic-disease-11639005991?mod=hp_lista_pos4","article_id":"1141494008","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141494008","pubTimestamp":1639009033,"sourceInfo":null,"weMediaInfo":null,"summary":"The U.S. Food and Drug Administration authorized a preventive antibody combination from AstraZeneca ","collect":0,"end_time":0,"defaultTopTitle":"wsj.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"AZN":"阿斯利康"},"translate_title":"阿斯利康新冠肺炎抗体被FDA授权作为预防症状性疾病的新工具","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":0.9},"content_text":"The U.S. Food and Drug Administration authorized a preventive antibody combination from AstraZeneca AZN 0.68% PLC that has shown strong efficacy in reducing risk of symptomatic Covid-19, offering a first-of-its-kind alternative for a minority of people for whom vaccines are considered less effective.\n\nThe antibody cocktail, called Evusheld, is aimed primarily for use in a minority of adolescents and adults age 12 and older with moderate to severely compromised immune systems. That may be because they have cancer or another illness or take medications or undergo treatments such as chemotherapy that inhibit an immune response to Covid-19 vaccines, the FDA said in a statement.\n\nAstraZeneca said earlier this year that it would aim the antibody combination, called AZD7442 and delivered as two consecutive shots, at preventing Covid-19 symptoms, like a vaccine. Emergency-use authorization from the FDA offers a new preventive option in addition to widely deployed vaccines.\n\nAstraZeneca said about seven million people in the U.S. may benefit from Evusheld to reduce their risk of symptomatic Covid-19 if taken before exposure.\n\nMonoclonal antibodies are the only drug treatments authorized for mild to moderate Covid-19 cases in people who aren’t sick enough to be hospitalized. The drugs, which are given by infusion or injection, provide a temporary substitute for the antibodies produced by the immune system to fight the virus after infection or vaccination.\n\nAstraZeneca’s drug is the first to get U.S. clearance to prevent Covid-19 in people who aren’t yet infected, but the company could face competition in the coming months. Rivals including Regeneron Pharmaceuticals Inc. are also seeking authorization for drugs to temporarily defend against infection.\n\nRegeneron said in November that its antibody drug REGEN-COV was 82% effective at preventing infection at least eight months after infusion in a study that included patients who hadn’t yet been exposed to the virus. Pfizer Inc. is also testing its antiviral pill Paxlovid to prevent infections in people recently exposed to the virus, which could provide another option for people with weakened immune systems.\n\n\nThe FDA said the authorization is for individuals not infected or recently exposed to someone infected with the virus. It said that vaccines remain “the best defense available against Covid-19.” In the agency’s statement, Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, said that Evusheld could help reduce the risk of Covid-19 in a subset of the population with a history of adverse reactions to Covid-19 vaccines or their components or with compromised immune systems.\n\n“Pre-exposure prevention with Evusheld is not a substitute for vaccination in individuals for whom Covid-19 vaccination is recommended,” the FDA said.\n\nThe antibody treatment is separate from AstraZeneca’s widely used Covid-19 vaccine developed in partnership with the University of Oxford. That vaccine is one of the most broadly distributed globally, with more than 2.2 billion doses delivered, but it isn’t authorized for use in the U.S.\n\nAstraZeneca said it’s testing Evusheld against the new Omicron variant. It “neutralizes all previous SARS-CoV-2 variants to date, and we are working quickly to establish its efficacy against the new Omicron variant,” said Mene Pangalos, the company’s executive vice president for biopharmaceuticals research and development, in a statement.\n\nSome scientists think that Omicron may have developed in a patient whose immune response was too weak to clear the virus, allowing it time to adapt and mutate. The rise of variants like Omicron highlights the need for treatments to better protect people who mount weak immune responses to the virus causing Covid-19, scientists say.\n\nThe company in August said Evusheld, also called AZD7442, showed 77% efficacy in reducing risk of symptomatic Covid-19 compared with a placebo in late-stage clinical trials testing its usefulness as a preventive treatment. In summarized preliminary findings, the company said that more than three-fourths of the 5,197 participants in the trial had comorbidities, or chronic disease, including conditions that could render vaccines less effective.\n\nProtection has been shown to last six months, the FDA and AstraZeneca said. Evaluation of the antibody combination is ongoing.\n\nMonoclonal antibody drugs are designed to mimic natural antibodies produced by the immune system to fight the coronavirus. AstraZeneca earlier hoped the therapy could be used to treat acute Covid-19 symptoms and stem infection to keep people already exposed to the virus out of the hospital. But the drug failed in late-stage trials for that primary purpose.\n\n\nEarlier in the pandemic, AstraZeneca received funding pledges that could exceed $700 million from the U.S. government to develop, test and potentially supply up to 700,000 doses of AZD7442 this year. The antibodies used were developed by Vanderbilt University Medical Center and licensed to AstraZeneca in June 2020.\n\nEuropean medicines regulators are also reviewing data for potential authorization of the antibody combination.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":602847732,"gmtCreate":1639010147327,"gmtModify":1639010147455,"author":{"id":"4090202748844200","authorId":"4090202748844200","name":"BotakTur","avatar":"https://static.tigerbbs.com/fbfb7690052b45745da7270aa672c42d","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/602847732","repostId":1141494008,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6907550,"gmtCreate":1639013832328,"gmtModify":1639013832357,"authorId":3574901428369611,"author":{"id":3574901428369611,"authorId":3574901428369611,"name":"BowenDu","avatar":"https://static.tigerbbs.com/b2b540981c00cc0005e6241f782bd3c5","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":602847732,"type":1,"supId":0,"prevId":0,"content":"<u>nice</u>","text":"<u>nice</u>","html":"<u>nice</u>"},{"id":6906260,"gmtCreate":1639010152153,"gmtModify":1639010152177,"authorId":4090202748844200,"author":{"id":4090202748844200,"authorId":4090202748844200,"name":"BotakTur","avatar":"https://static.tigerbbs.com/fbfb7690052b45745da7270aa672c42d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":602847732,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"CN"},{"id":602842462,"gmtCreate":1639009917604,"gmtModify":1639009917769,"author":{"id":"3578990746736424","authorId":"3578990746736424","name":"Botak Tur","avatar":"https://static.tigerbbs.com/ad2db38166c18b512749a83019596279","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/602842462","repostId":1141494008,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6906174,"gmtCreate":1639009922375,"gmtModify":1639009922402,"authorId":3578990746736424,"author":{"id":3578990746736424,"authorId":3578990746736424,"name":"Botak Tur","avatar":"https://static.tigerbbs.com/ad2db38166c18b512749a83019596279","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":602842462,"type":1,"supId":0,"prevId":0,"content":"K","text":"K","html":"K"}],"langContent":"CN"},{"id":602841258,"gmtCreate":1639009600120,"gmtModify":1639009600314,"author":{"id":"4097384260129050","authorId":"4097384260129050","name":"Kaden0204","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602841258","repostId":1141494008,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":602841191,"gmtCreate":1639009585206,"gmtModify":1639009585351,"author":{"id":"3572761324363640","authorId":"3572761324363640","name":"SamuelNg","avatar":"https://static.tigerbbs.com/758b132d63959927e156935f0c64d8e9","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/602841191","repostId":1141494008,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":82,"commentSize":4,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1141494008"}